The U.S. Food and Drug Administration has approved once-daily Onyda XR (clonidine hydrochloride) as the first liquid, ...

Beta-blockers are effective at decreasing the morbidity and mortality associated with CHF. They lower the risk of all-cause mortality, cardiovascular mortality, sudden death, and death from ...

This is not routinely recommended by veterinarians. The main class of non-hormonal medications for urinary incontinence is alpha-adrenergic agonists. These medications act on the receptors of the ...

Xylazine, often found in street-drug combination with fentanyl, was thought to only bind to the α2-adrenergic receptor, but UNC-Chapel Hill scientists discovered it also binds to opioid receptors, ...

They administered the xylazine-based conjugates to mice and monitored how the mice moved and breathed when they were later ...

Tris Pharma on Wednesday secured the FDA’s green light for Onyda XR, the first liquid non-stimulant nighttime treatment for ...

In a study published in Cell Host & Microbe, a research team has demonstrated the causal link between microbial factors and ...

The crystal structure of a second G protein–coupled receptor sheds light on these key pharmaceutical targets. In contrast, β2AR and essentially all of the other GPCRs are present at very low ...

Explore Ohio's dynamic biotech scene, where leading companies drive innovation and contribute to healthcare advancements.

Some commonly used asthma medicines, such as theophylline and beta-adrenergic bronchodilators, may even aggravate acid reflux. Consult with your healthcare professional before changing or stopping ...

Preclinical data shows precision modulation of beta-2 and beta-3 signaling boosts metabolism and enhances body ...

Onyda XR, a centrally acting alpha 2-adrenergic agonist, was approved based on adequate and well-controlled studies of clonidine hydrochloride extended-release tablets. The non-stimulant treatment is ...